In addition to controlling hyperglycemia, hypertension, and hyperlipidemia, pharmaceutical drugs like renin–angiotensin system inhibitors (RASi) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) are mainly used in treating DKD. The gene discussed is MMP19; the disease is diabetic kidney disease.